EMA meeting on Pfizer and BioNTech vaccine next week

15 December 2020

ema_conference-room-xl_credit_rob-acket_large

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has set a date to discuss BioNTech (Nasdaq: BNTX) and Pfizer’s (NYSE: PFE) conditional marketing authorization (CMA) application for BNT162b2, a COVID‑19 mRNA vaccine.

Following receipt on Monday of additional data requested by the committee from the applicants and pending the outcome of its evaluation, an exceptional meeting of the CHMP has now been scheduled for December 21.

It is hoped that occasion will be enough to make a determination on the application, but the meeting planned for December 29 will be maintained if needed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK